Thousands of men are set to receive a groundbreaking prostate cancer medication through the NHS in the coming weeks. Patients with localized cancer will soon have access to abiraterone in England as the healthcare system broadens its treatment offerings. Approximately 2,000 individuals diagnosed in the last three months will be granted access to the drug initially, with an additional 7,000 men expected to qualify each year.
Abiraterone, an oral tablet prescribed to halt cancer progression by depriving the disease of essential hormones, has demonstrated impressive results. NHS research indicates that the survival rate after six years on abiraterone was 86%, surpassing the 77% rate on standard therapy.
Prostate cancer is the most prevalent cancer among men and the second most common overall in the UK, with more than 55,000 new cases reported annually. Cancer Research UK reports these statistics. The recent approval of abiraterone for a larger pool of eligible patients underscores the government’s dedication to combatting the disease, according to Health and Social Care Secretary Wes Streeting.
Professor Peter Johnson, National Clinical Director for Cancer at NHS England, highlighted the potential life-changing impact of this treatment option for thousands of men with prostate cancer. This imminent availability of a life-extending treatment on the NHS will offer hope to numerous individuals by improving their chances of longer and healthier lives.
Meanwhile, researchers at the University of Cambridge are working on a cutting-edge blood test that could revolutionize prostate cancer diagnosis. This innovative test, using DNA methylation markers to detect cancer presence and severity accurately, shows promising advancements in cancer detection technology. Men who have previously undergone the PSA test may benefit from this new blood test, potentially avoiding invasive biopsy procedures.